Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6310MR)

This product GTTS-WQ6310MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors, research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6310MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6816MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ13760MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ7510MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ6311MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ11932MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ8989MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ7548MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW